PT  - JOURNAL ARTICLE
AU  - J.-P. Renne
AU  - G. Roussellet
AU  - G. Schwenkler
TI  - Preventing COVID-19 Fatalities: State versus Federal Policies
AID  - 10.1101/2020.10.28.20221952
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.28.20221952
4099  - http://medrxiv.org/content/early/2020/12/15/2020.10.28.20221952.short
4100  - http://medrxiv.org/content/early/2020/12/15/2020.10.28.20221952.full
AB  - Are COVID-19 fatalities large when a federal government does not enforce containment policies and instead allow states to implement their own policies? We answer this question by developing a stochastic extension of a SIRD epidemiological model for a country composed of multiple states. Our model allows for interstate mobility. We consider three policies: mask mandates, stay-at-home orders, and interstate travel bans. We fit our model to daily U.S. state-level COVID-19 death counts and exploit our estimates to produce various policy counterfactuals. While the restrictions imposed by some states inhibited a significant number of virus deaths, we find that more than two-thirds of U.S. COVID-19 deaths could have been prevented by late November 2020 had the federal government enforced federal mandates as early as some of the earliest states did. Our results quantify the benefits of early actions by a federal government for the containment of a pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere were no funding sources.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:There were no clinical studies carried out for this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is publicly available. The codes used in this paper are available at https://github.com/guillaume-roussellet/RRS_Covid_2020.git. https://github.com/guillaume-roussellet/RRS_Covid_2020.git